Registrera för att skapa bevakningar för instrument,
ekonomiska händelser och innehåll av författare som följs
Gratis registrering Har du redan ett konto? Logga in
Värdering
Alla instrumenttyper
- Alla instrumenttyper
- Index
- Aktier
- ETF
- Fonder
- Råvaror
- Valutor
- Krypto
- Obligationer
- Certifikat
Prova en annan sökning
🐦 Early bird hittar de hetaste aktierna till ett lägre pris. Få upp till 55 % rabatt på InvestingPro under Black Friday
HÄMTA REA
Fidelity Select Pharmaceuticals Portfolio (FPHAX)
Lägg till/Ta bort från en portfölj
Lägg till portföljen
26,67
+0,32
+1,21%
22/11 - Stängd. Valuta i USD
- Morningstar-värdering:
- Totala tillgångar: 1,67B
Fidelity Select Pharmaceuticals Port
26,67
+0,32
+1,21%
- Översikt
- Profil
- Historiska data
- Innehav
FPHAX Översikt
På denna sida hittar du en djupgående profil av Fidelity Select Pharmaceuticals Portfolio. Läs om viktig ledning, totala tillgångar, investeringsstrategi och kontaktinformation om FPHAX tillsammans med annan information.
Kontaktinformation
Adress
483 Bay Street
Toronto,ON M5G 2N7
Canada
Toronto,ON M5G 2N7
Canada
Telefon
416-307-5200
Fax
1-800-387-8092
Verkställande ledning
| Namn | Titel | Sedan | Till |
|---|---|---|---|
| Karim Suwwan de Felipe | Research Analyst/Portfolio Manager | 2017 | Nu |
| Biografi | Karim Suwwan de Felipe is a research analyst and portfolio manager in the Equity division at Fidelity Investments. Fidelity Investments is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing, and other financial products and services to institutions, financial intermediaries, and individuals. In this role, Mr. Suwwan de Felipe is responsible for covering and providing recommendations on stocks in the global pharmaceutical sector. Additionally, he manages the Fidelity Select Pharmaceuticals Portfolio. Prior to joining Fidelity in 2010, Mr. Suwwan de Felipe was a senior research associate at Citi Investment Research and Analysis. As a member of the biotechnology research team at Citi, he helped formulate recommendations on large and mid-cap biotechnology equities. Previously, Mr. Suwwan de Felipe conducted molecular biology research at CuraGen Corporation, a biotechnology company in Connecticut, and at Yale University’s Department of Therapeutic Radiology. Mr. Suwwan de Felipe earned his bachelor of science degree in molecular biophysics and biochemistry from Yale University, and his doctorate degree with distinction in cellular, molecular, and biophysical studies from Columbia University’s College of Physicians and Surgeons. | ||
| Asher Anolic | Portfolio Manager | 2013 | 2018 |
| Biografi | Asher Anolic is co-manager of the VIP Growth Portfolio, which he has managed since July 2017. He also manages other funds. Since joining Fidelity Investments in 2008, Mr. Anolic has worked as a research analyst and portfolio manager. Prior to joining Fidelity Investments in 2008, Mr. Anolic worked for Bear Stearns as a research analyst. | ||
| Andrew Oh | Equity Research Analyst | 2006 | 2013 |
| Biografi | Oh joined Fidelity Investments in 2006 as an equity research analyst. Prior to Fidelity, he was director and senior pharmaceuticals analyst for Leernik Swann & Company in New York. From 2001 to 2004, he was senior equity research associate following the U.S. large cap pharmaceuticals sector for JP Morgan Chase in New York. | ||
| Harlan P. Carere | Portfolio Manager | 2005 | 2007 |
| Biografi | Carere is a portfolio manager of Fidelity Investments. He joined Fidelity International Limited in London in 2000 as an equity research analyst following the technology sector. He subsequently served as technology sector leader in the London office. Prior to joining the firm, he was an equity analyst for Berman Capital. | ||
| Ian Gutterman | Portfolio Manager | 2005 | 2005 |
| Biografi | Gutterman is a portfolio manager with Fidelity Investments, his employer since 1999. Prior to joining the firm, he was a treasury analyst with MT Bank from 1995 to 1997. | ||
| Gavin Baker | Sector Leader | 2002 | 2005 |
| Biografi | Baker joined Fidelity in 1999 as an equity research analyst following companies in the cement and building materials industries. He subsequently followed the semiconductor industry. In 2002, Baker began following the pharmaceutical sector, and managed Fidelity Select Pharmaceuticals Portfolio from 2002 to 2005. He then started following large- cap consumer stocks before assuming — in 2006 —the role of diversified analyst working with the large– cap growth group. Baker most recently began serving as sector leader of the telecom and utilities equity research group. | ||
| Yolanda S. Strock | equity analyst/portfolio Manager | 2001 | 2002 |
| Biografi | Yolanda Strock joined Fidelity in 1997 where she is the sector leader of the Health Care Equity Resesarch group. She began managing Fidelity Select Biotechnology Portfolio in February 2000, and assumed her other fund management responsibilities and role of sector leader in June 2000. Yolanda has an MBA in Finance from the Fuqua School of Business at Duke University, a BSc in Marketing from the Wharton School of Business and a BA in economics from the University of Pennsylvania. | ||
Skriv dina tankar om Fidelity Select Pharmaceuticals Portfolio
Aär du säker på att du vill ta bort det här diagrammet?
Radera Avbryt
Ersätt det bifogade diagrammet med ett nytt?
Byt ut Avbryt
Riktlinjer för kommentarer
Lägg till diagram till kommentar
Bekräfta blockering
Är du säker på att du vill blockera %USER_NAME%?
Genom att blockera kan du och %USER_NAME% inte se varandras inlägg på Investing.com.
%USER_NAME% lyckades läggas till i din Blockeringslista
Eftersom du precis avblockerat denna person måste du vänta 48 timmar för att kunna förnya blockeringen.
Rapportera den här kommentaren
Jag anser att denna kommentar är:
Kommentar flaggad
Tack!
Rapporten har skickats till våra moderatorer för granskning